1. |
Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289:1681-90.
|
2. |
Toth PP, Harper CR, Jacobson TA. Clinical charac- terization and molecular mechanisms of statin myopathy. Expert Rev Cardiovasc Ther 2008; 6:955-69.
|
3. |
Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001; 35:1096-107.
|
4. |
Manzoni M, Rollini M. Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs. Appl Microbiol Biotechnol 2002; 58:555-64.
|
5. |
Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007; 49:2231-7.
|
6. |
Liantonio A, Giannuzzi V, Cippone V, et al. Fluvastatin and atorvastatin affect calcium homeostasis of rat skeletal muscle fibers in vivo and in vitro by impairing the sarcoplasmic reticulum/mitochondria Ca 2+ -release system. J Pharmacol Exp Ther 2007; 321:626-34.
|
7. |
Mickelson JR, Louis CF. Malignant hyperthermia: excitation- contraction coupling, Ca 2+ release channel, and cell Ca 2+ regulation defects. Physiol Rev 1996; 76:537-92.
|
8. |
Larach MG, Localio AR, Allen GC, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80:771-9.
|
9. |
Hopkins PM. Malignant hyperthermia: advances in clinical management and diagnosis. Br J Anaesth 2000; 85: 118-28.
|
10 |
Krivosic-Horber R, Dépret T, Wagner JM, et al. Malignant hyperthermia susceptibility revealed by increased serum creatine kinase concentrations during statin treatment. Eur J Anaesthesiol 2004; 21:572-4.
|
11 |
Guis S, Bendahan D, Kozak-Ribbens G, et al. Rhabdomyolysis and myalgia associated with anticholesterolemic treatment as potential signs of malignant hyperthermia susceptibility. Arthritis Rheum 2003; 49:237-8.
|
12 |
Evans TJ, Parent CM, McGunigal MP. Atypical presentation of malignant hyperthermia. Anesthesiology 2002; 97:507-8.
|
13 |
Nakahara K, Yada T, Kuriyama M, et al. Cytosolic Ca 2+ increase and cell damage in L6 rat myoblasts by HMG- CoA reductase inhibitors. Biochem Biophys Res Commun 1994; 202:1579-85.
|
14 |
Wehner M, Rueffert H, Koenig F, et al. Functional characterization of malignant hyperthermia-associated RyR1 mutations in exon 44, using the human myotube model. Neuromuscul Disord 2004; 14:429-37.
|
15 |
Masters BA, Palmoski MJ, Flint OP, et al. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and sim- vastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol 1995; 131:163-74.
|
16 |
Vandenburgh HH, Karlisch P, Farr L. Maintenance of highly contractile tissue-cultured avian skeletal myotubes in collagen gel. In Vitro Cell Dev Biol 1988; 24:166-74.
|
17 |
Duke AM, Hopkins PM, Steele DS. Effects of Mg(2+) and SR luminal Ca(2+) on caffeine-induced Ca(2+) release in skeletal muscle from humans susceptible to malignant hyperthermia. J Physiol 2002; 544:85-95.
|
18 |
Wehner M, Rueffert H, Koenig F,et al. Increased sensitivity to 4-chloro-m-cresol and caffeine in primary myotubes from malignant hyperthermia susceptible individuals carrying the ryanodine receptor 1 Thr2206Met (C6617T) mutation. Clin Genet 2002; 62:135-46.
|
19 |
Sirvent P, Mercier J, Vassort G, et al. Simvastatin triggers mitochondria-induced Ca 2+ signaling alteration in skeletal muscle. Biochem Biophys Res Commun 2005; 329: 1067-75.
|
20 |
Lamb GD, Cellini MA, Stephenson DG, et al. Toxicity of statins on rat skeletal muscle mitochondria. J Physiol 2001; 531:715-28.
|
21 |
Lamb GD, Cellini MA, Stephenson DG. Different Ca 2+ releasing action of caffeine and depolarisation in skeletal muscle fibres of the rat. J Physiol 2001; 531:715-28.
|
22 |
22.López JR, Contreras J, Linares N, et al. Hypersensitivity of malignant hyperthermia-susceptible swine skeletal muscle to caffeine is mediated by high resting myoplasmic [Ca 2+ ]. Anesthesiology 2000; 92:1799-806.
|
23 |
Snowdowne KW. Subcontracture depolarizations increase sarcoplasmic ionized calcium in frog skeletal muscle. Am J Physiol 1985; 248:C520-C6.
|
24 |
24.Pierno S, Didonna MP, Cippone V, et al. Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study. Br J Pharmacol 2006; 149:909-19.
|
25 |
Itagaki M, Takaguri A, Kano S, et al. Possible mechanisms underlying statin-induced skeletal muscle toxicity in L6 fibroblasts and in rats. J Pharmacol Sci 2009; 109: 94-101.
|
26 |
Klip A, Hill M, Ramlal T. Halothane increases cytosolic Ca 2+ and inhibits Na + /H + exchange in L6 muscle cells. J Pharmacol Exp Ther 1990; 254:552-9.
|